Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)

This post-marketing surveillance study is to investigate the efficacy and safety of azathioprine tablets in subjects whom lung transplantation is performed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Diseases Digestive System Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects who undergo lung transplantation and azathioprine tablets were administered

Exclusion criteria

Subjects with hypersensitivity to the ingredients of azathioprine tablet
Subjects who is pregnant or might be pregnant
Subjects whose white count is lower than 3000/cubic millimeter

Treatment and study plan

azathioprine

Drug

At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.

Primary outcomes

Incidence of adverse events related to azathioprine tablets

Time frame: 3 years

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Important dates

Study start: 2004
Primary completion: 2011
Study completion: 2011
First posted: Jun 27, 2011
Registry last updated: May 13, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed